文献速递血脂与心血管预防

降脂治疗从他汀到PCSK9抑制剂的进展

Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

综述指出孟德尔随机化研究与随机试验证实降低低密度脂蛋白胆固醇(LDL-C)可减少心血管事件。超过25项心血管结局试验显示,他汀每降低38.7 mg/dl(1 mmol/l)LDL-C,主要动脉粥样硬化事件相对风险降低约22%,且各亚组获益相似。其他药物如依折麦布和PCSK9抑制剂按LDL-C降幅成比例减少事件,安全性良好但PCSK9抑制剂昂贵。

要点

  • 他汀每降38.7 mg/dl LDL-C,主要动脉粥样硬化事件相对风险降约22%。
  • 他汀对非血管性死亡和癌症的安全性已获荟萃分析支持。
  • 依折麦布和PCSK9抑制剂按LDL-C降幅成比例减少事件,安全性良好。

核心结论

  • 降低LDL-C可减少心血管事件,他汀、依折麦布和PCSK9抑制剂均按LDL-C降幅成比例降低风险。

研究设计与样本

  • 综述总结了从孟德尔随机化研究到随机试验的降脂治疗证据。
  • 数据来自超过25项心血管结局试验。

主要发现

  • 超过25项心血管结局试验显示他汀在数年内使主要动脉粥样硬化事件相对风险降低约22%/38.7 mg/dl(1 mmol/l)LDL-C降幅。
  • 他汀获益在患者亚组间相似。
  • 荟萃分析确立他汀对非血管性死亡和癌症的安全性。
  • 依折麦布和PCSK9抑制剂按LDL-C降幅成比例减少主要动脉粥样硬化事件,安全性良好,但PCSK9抑制剂仍昂贵。
  • 正在心血管结局研究中测试的药物包括bempedoic acid和inclisiran。

关键数值与推荐

  • 他汀:每降低38.7 mg/dl(1 mmol/l)LDL-C,主要动脉粥样硬化事件相对风险降低约22%。

临床怎么用

  • 临床可依据LDL-C降幅选择他汀、依折麦布或PCSK9抑制剂以降低动脉粥样硬化事件风险。
  • 需权衡PCSK9抑制剂的成本与获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL cholesterol-lowering treatment. Data from over 25 cardiovascular outcome trials confirm that, within a few years, statins lower the relative risk of major atherosclerotic events by about 22% per 38.7 mg/dl (1 mmol/l) reduction in LDL cholesterol, with similar benefit across patient subgroups. Meta-analyses of these trials have established the safety of statins with regard to nonvascular mortality and cancer. Other agents available for prescription include ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which both reduce major atherosclerotic events in proportion to their effects on LDL cholesterol and have good safety profiles, though PCSK9 inhibitors remain costly. Investigational LDL cholesterol-lowering agents currently being tested in cardiovascular outcome studies are bempedoic acid, an adenosine triphosphate-citrate lyase inhibitor that reduces cholesterol synthesis, and inclisiran, a double-stranded small interfering ribonucleic acid that inhibits PCSK9 synthesis.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Preiss D, Tobert JA, Hovingh GK, et al. Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar. J Am Coll Cardiol. 2020. PMID: 32327106. doi:10.1016/j.jacc.2019.11.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。